Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Metastasis | Research

The E3 ligase NEURL3 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma by promoting vimentin degradation

Authors: Shi-Qing Zhou, Ping Feng, Ming-Liang Ye, Sheng-Yan Huang, Shi-Wei He, Xun-Hua Zhu, Jun Chen, Qun Zhang, Ying-Qing Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Background

Metastasis has emerged as the major reason of treatment failure and mortality in patients with nasopharyngeal carcinoma (NPC). Growing evidence links abnormal DNA methylation to the initiation and progression of NPC. However, the precise regulatory mechanism behind these processes remains poorly understood.

Methods

Bisulfite pyrosequencing, RT-qPCR, western blot, and immunohistochemistry were used to test the methylation and expression level of NEURL3 and its clinical significance. The biological function of NEURL3 was examined both in vitro and in vivo. Mass spectrometry, co-immunohistochemistry, immunofluorescence staining, and ubiquitin assays were performed to explore the regulatory mechanism of NEURL3.

Results

The promoter region of NEURL3, encoding an E3 ubiquitin ligase, was obviously hypermethylated, leading to its downregulated expression in NPC. Clinically, NPC patients with a low NEURL3 expression indicated an unfavorable prognosis and were prone to develop distant metastasis. Overexpression of NEURL3 could suppress the epithelial mesenchymal transition and metastasis of NPC cells in vitro and in vivo. Mechanistically, NEURL3 promoted Vimentin degradation by increasing its K48-linked polyubiquitination at lysine 97. Specifically, the restoration of Vimentin expression could fully reverse the tumor suppressive effect of NEURL3 overexpression in NPC cells.

Conclusions

Collectively, our study uncovers a novel mechanism by which NEURL3 inhibits NPC metastasis, thereby providing a promising therapeutic target for NPC treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64–80.PubMedCrossRef Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64–80.PubMedCrossRef
2.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMedCrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMedCrossRef
3.
go back to reference Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Nasopharyngeal cancer: molecular landscape. J Clin Oncol. 2015;33:3346–55.PubMedCrossRef Bruce JP, Yip K, Bratman SV, Ito E, Liu FF. Nasopharyngeal cancer: molecular landscape. J Clin Oncol. 2015;33:3346–55.PubMedCrossRef
4.
go back to reference Qiao H, Tan XR, Li H, Li JY, Chen XZ, Li YQ, et al. Association of intratumoral microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in China. JAMA Oncol. 2022;8(9):1301–9.PubMedPubMedCentralCrossRef Qiao H, Tan XR, Li H, Li JY, Chen XZ, Li YQ, et al. Association of intratumoral microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in China. JAMA Oncol. 2022;8(9):1301–9.PubMedPubMedCentralCrossRef
5.
go back to reference Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021;41:1195–27.PubMedCrossRef Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021;41:1195–27.PubMedCrossRef
6.
go back to reference Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol. 2022;40(22):2420–5.PubMedCrossRef Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial. J Clin Oncol. 2022;40(22):2420–5.PubMedCrossRef
7.
go back to reference Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303–13.PubMedCrossRef Chen YP, Liu X, Zhou Q, Yang KY, Jin F, Zhu XD, et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021;398(10297):303–13.PubMedCrossRef
8.
go back to reference Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46(8):866–71.PubMedCrossRef Lin DC, Meng X, Hazawa M, Nagata Y, Varela AM, Xu L, et al. The genomic landscape of nasopharyngeal carcinoma. Nat Genet. 2014;46(8):866–71.PubMedCrossRef
9.
go back to reference Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(40):11283–8.PubMedPubMedCentralCrossRef Zheng H, Dai W, Cheung AKL, Ko JMY, Kan R, Wong BWY, et al. Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(40):11283–8.PubMedPubMedCentralCrossRef
10.
go back to reference Li YY, Chuang GT, Lui VW, To KF, Ma BB, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kB pathway activating mutations. Nat Commun. 2017;8:14121.PubMedPubMedCentralCrossRef Li YY, Chuang GT, Lui VW, To KF, Ma BB, Chow C, et al. Exome and genome sequencing of nasopharynx cancer identifies NF-kB pathway activating mutations. Nat Commun. 2017;8:14121.PubMedPubMedCentralCrossRef
11.
go back to reference Dai W, Zheng H, Cheung AK, Lung ML. Genetic and epigenetic landscape of nasopharyngeal carcinoma. Chin Clin Oncol. 2016;5(2):16.PubMedCrossRef Dai W, Zheng H, Cheung AK, Lung ML. Genetic and epigenetic landscape of nasopharyngeal carcinoma. Chin Clin Oncol. 2016;5(2):16.PubMedCrossRef
12.
13.
go back to reference Dai W, Cheung AKL, Ko JMY, Cheng Y, Zheng H, Ngan RKC, et al. Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. Cancer Med. 2015;4:1079–90.PubMedPubMedCentralCrossRef Dai W, Cheung AKL, Ko JMY, Cheng Y, Zheng H, Ngan RKC, et al. Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. Cancer Med. 2015;4:1079–90.PubMedPubMedCentralCrossRef
14.
go back to reference Jiang W, Liu N, Chen XZ, Sun Y, Li B, Ren XY, et al. Genome-wide identification of a methylation gene panel as a prognostic biomarker in nasopharyngeal carcinoma. Mol Cancer Ther. 2015;14(12):2864–73.PubMedCrossRef Jiang W, Liu N, Chen XZ, Sun Y, Li B, Ren XY, et al. Genome-wide identification of a methylation gene panel as a prognostic biomarker in nasopharyngeal carcinoma. Mol Cancer Ther. 2015;14(12):2864–73.PubMedCrossRef
15.
go back to reference Ren XY, Zhou GQ, Jiang W, Sun Y, Xu YF, Li YQ, et al. Low SFRP1 expression correlates with poor prognosis and promotes cell invasion by activating the Wnt-β-catenin signaling pathway in NPC. Cancer Prev Res. 2015;8(10):968–77.CrossRef Ren XY, Zhou GQ, Jiang W, Sun Y, Xu YF, Li YQ, et al. Low SFRP1 expression correlates with poor prognosis and promotes cell invasion by activating the Wnt-β-catenin signaling pathway in NPC. Cancer Prev Res. 2015;8(10):968–77.CrossRef
16.
go back to reference Ren XY, Yang XJ, Cheng B, Chen XZ, Zhang TP, He QM, et al. HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma. Nat Commun. 2017;8:14053.PubMedPubMedCentralCrossRef Ren XY, Yang XJ, Cheng B, Chen XZ, Zhang TP, He QM, et al. HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma. Nat Commun. 2017;8:14053.PubMedPubMedCentralCrossRef
17.
go back to reference Zhang J, Li YQ, Guo R, Wang YQ, Zhang PP, Tang XR, et al. Hypermethylation of SHISA3 promotes nasopharyngeal carcinoma metastasis by reducing SGSM1 stability. Cancer Res. 2019;79(4):747–59.PubMedCrossRef Zhang J, Li YQ, Guo R, Wang YQ, Zhang PP, Tang XR, et al. Hypermethylation of SHISA3 promotes nasopharyngeal carcinoma metastasis by reducing SGSM1 stability. Cancer Res. 2019;79(4):747–59.PubMedCrossRef
18.
go back to reference Chen Y, Zhao Y, Yang X, Ren X, Huang S, Gong S, et al. USP44 regulates irradiation-induced DNA double-strand break repair and suppresses tumorigenesis in nasopharyngeal carcinoma. Nat Commun. 2022;13(1):501.PubMedPubMedCentralCrossRef Chen Y, Zhao Y, Yang X, Ren X, Huang S, Gong S, et al. USP44 regulates irradiation-induced DNA double-strand break repair and suppresses tumorigenesis in nasopharyngeal carcinoma. Nat Commun. 2022;13(1):501.PubMedPubMedCentralCrossRef
19.
go back to reference Walma DCA, Chen Z, Bullock AN, Yamada KM. Ubiquitin ligases: guardians of mammalian development. Nat Rev Mol Cell Biol. 2022;23(5):350–67.CrossRef Walma DCA, Chen Z, Bullock AN, Yamada KM. Ubiquitin ligases: guardians of mammalian development. Nat Rev Mol Cell Biol. 2022;23(5):350–67.CrossRef
20.
go back to reference Sosič I, Bricelj A, Steinebach C. E3 ligase ligand chemistries: from building blocks to protein degraders. Chem Soc Rev. 2022;51(9):3487–534.PubMedCrossRef Sosič I, Bricelj A, Steinebach C. E3 ligase ligand chemistries: from building blocks to protein degraders. Chem Soc Rev. 2022;51(9):3487–534.PubMedCrossRef
21.
go back to reference Sherpa D, Chrustowicz J, Schulman BA. How the ends signal the end: regulation by E3 ubiquitin ligases recognizing protein termini. Mol cell. 2022;82(8):1424–38.PubMedPubMedCentralCrossRef Sherpa D, Chrustowicz J, Schulman BA. How the ends signal the end: regulation by E3 ubiquitin ligases recognizing protein termini. Mol cell. 2022;82(8):1424–38.PubMedPubMedCentralCrossRef
22.
go back to reference Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6(10):776–88.PubMedCrossRef Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6(10):776–88.PubMedCrossRef
23.
go back to reference Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11.PubMedPubMedCentralCrossRef Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020;5(1):11.PubMedPubMedCentralCrossRef
24.
go back to reference Fang S, Lorick KL, Jensen JP, Weissman AM. RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol. 2003;13(1):5–14.PubMedCrossRef Fang S, Lorick KL, Jensen JP, Weissman AM. RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol. 2003;13(1):5–14.PubMedCrossRef
25.
go back to reference Smith JB, Nguyen TT, Hughes HJ, Herschman HR, Widney DP, Bui KC, et al. Glucocorticoid-attenuated response genes induced in the lung during endotoxemia. Am J Physiol Lung Cell Mol Physiol. 2002;283(3):L636–47.PubMedCrossRef Smith JB, Nguyen TT, Hughes HJ, Herschman HR, Widney DP, Bui KC, et al. Glucocorticoid-attenuated response genes induced in the lung during endotoxemia. Am J Physiol Lung Cell Mol Physiol. 2002;283(3):L636–47.PubMedCrossRef
26.
go back to reference Smith JB, Herschman HR. Targeted identification of glucocorticoid-attenuated response genes: in vitro and in vivo models. Proc Am Thorac Soc. 2004;1(3):275–81.PubMedCrossRef Smith JB, Herschman HR. Targeted identification of glucocorticoid-attenuated response genes: in vitro and in vivo models. Proc Am Thorac Soc. 2004;1(3):275–81.PubMedCrossRef
27.
go back to reference Qi F, Zhang X, Wang L, Ren C, Zhao X, Luo J, et al. E3 ubiquitin ligase NEURL3 promotes innate antiviral response through catalyzing K63-linked ubiquitination of IRF7. FASEB J. 2022;36(8):e22409.PubMedCrossRef Qi F, Zhang X, Wang L, Ren C, Zhao X, Luo J, et al. E3 ubiquitin ligase NEURL3 promotes innate antiviral response through catalyzing K63-linked ubiquitination of IRF7. FASEB J. 2022;36(8):e22409.PubMedCrossRef
28.
go back to reference Zhao Y, Cao X, Guo M, Wang X, Yu T, Ye L, et al. Neuralized E3 ubiquitin protein ligase 3 is an inducible antiviral effector that inhibits hepatitis C virus assembly by targeting viral E1 glycoprotein. J Virol. 2018;92(21):e01123–18.PubMedPubMedCentralCrossRef Zhao Y, Cao X, Guo M, Wang X, Yu T, Ye L, et al. Neuralized E3 ubiquitin protein ligase 3 is an inducible antiviral effector that inhibits hepatitis C virus assembly by targeting viral E1 glycoprotein. J Virol. 2018;92(21):e01123–18.PubMedPubMedCentralCrossRef
29.
go back to reference Londhe VA, Tomi T, Nguyen TT, Lopez B, Smith JB. Overexpression of LINCR in the developing mouse lung epithelium inhibits distal differentiation and induces cystic changes. Dev Dyn. 2015;244(7):827–38.PubMedCrossRef Londhe VA, Tomi T, Nguyen TT, Lopez B, Smith JB. Overexpression of LINCR in the developing mouse lung epithelium inhibits distal differentiation and induces cystic changes. Dev Dyn. 2015;244(7):827–38.PubMedCrossRef
30.
go back to reference Xu W, Li H, Dong Z, Cui Z, Zhang N, Meng L, et al. Ubiquitin ligase gene neurl3 plays a role in spermatogenesis of half-smooth tongue sole (Cynoglossus semilaevis) by regulating testis protein ubiquitination. Gene. 2016;592(1):215–20.PubMedCrossRef Xu W, Li H, Dong Z, Cui Z, Zhang N, Meng L, et al. Ubiquitin ligase gene neurl3 plays a role in spermatogenesis of half-smooth tongue sole (Cynoglossus semilaevis) by regulating testis protein ubiquitination. Gene. 2016;592(1):215–20.PubMedCrossRef
31.
go back to reference Zhang L, MacIsaac KD, Zhou T, Huang PY, Xin C, Dobson JR, et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. Mol Cancer Res. 2017;15(12):1722–32.PubMedCrossRef Zhang L, MacIsaac KD, Zhou T, Huang PY, Xin C, Dobson JR, et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-based subtypes. Mol Cancer Res. 2017;15(12):1722–32.PubMedCrossRef
32.
go back to reference Zhong L, Liao D, Li J, Liu W, Wang J, Zeng C, et al. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. Signal Transduct Target Ther. 2021;6(1):59.PubMedPubMedCentralCrossRef Zhong L, Liao D, Li J, Liu W, Wang J, Zeng C, et al. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes. Signal Transduct Target Ther. 2021;6(1):59.PubMedPubMedCentralCrossRef
33.
go back to reference Pang K, Park J, Ahn SG, Lee J, Park Y, Ooshima A, et al. RNF208, an estrogen-inducible E3 ligase, targets soluble vimentin to suppress metastasis in triple-negative breast cancers. Nat Commun. 2019;10(1):5805.PubMedPubMedCentralCrossRef Pang K, Park J, Ahn SG, Lee J, Park Y, Ooshima A, et al. RNF208, an estrogen-inducible E3 ligase, targets soluble vimentin to suppress metastasis in triple-negative breast cancers. Nat Commun. 2019;10(1):5805.PubMedPubMedCentralCrossRef
34.
go back to reference Shao W, Li J, Piao Q, Yao X, Li M, Wang S, et al. FRMD3 inhibits the growth and metastasis of breast cancer through the ubiquitination-mediated degradation of vimentin and subsequent impairment of focal adhesion. Cell Death Dis. 2023;14(1):13.PubMedPubMedCentralCrossRef Shao W, Li J, Piao Q, Yao X, Li M, Wang S, et al. FRMD3 inhibits the growth and metastasis of breast cancer through the ubiquitination-mediated degradation of vimentin and subsequent impairment of focal adhesion. Cell Death Dis. 2023;14(1):13.PubMedPubMedCentralCrossRef
36.
go back to reference Kuburich NA, den Hollander P, Pietz JT, Mani SA. Vimentin and cytokeratin: good alone, bad together. Semin Cancer Biol. 2022;86(Pt 3):816–26.PubMedCrossRef Kuburich NA, den Hollander P, Pietz JT, Mani SA. Vimentin and cytokeratin: good alone, bad together. Semin Cancer Biol. 2022;86(Pt 3):816–26.PubMedCrossRef
38.
go back to reference Luo W, Fang W, Li S, Yao K. Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Int J Cancer. 2012;131(8):1863–73.PubMedCrossRef Luo W, Fang W, Li S, Yao K. Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Int J Cancer. 2012;131(8):1863–73.PubMedCrossRef
39.
go back to reference Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, The AY, et al. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers (Basel). 2021;13(19):4985.PubMedCrossRef Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, The AY, et al. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers (Basel). 2021;13(19):4985.PubMedCrossRef
40.
go back to reference Carnero A, Lleonart M. The hypoxic microenvironment: a determinant of cancer stem cell evolution. BioEssays. 2016;38:65–74.CrossRef Carnero A, Lleonart M. The hypoxic microenvironment: a determinant of cancer stem cell evolution. BioEssays. 2016;38:65–74.CrossRef
41.
go back to reference Prieto-Vila M, Usuba W, Takahashi RU, Shimomura I, Sasaki H, Ochiya T, et al. Single-cell analysis reveals a preexisting drug-resistant subpopulation in the luminal breast cancer subtype. Cancer Res. 2019;79(17):4412–25.PubMedCrossRef Prieto-Vila M, Usuba W, Takahashi RU, Shimomura I, Sasaki H, Ochiya T, et al. Single-cell analysis reveals a preexisting drug-resistant subpopulation in the luminal breast cancer subtype. Cancer Res. 2019;79(17):4412–25.PubMedCrossRef
42.
go back to reference van Beijnum JR, Huijbers EJM, van Loon K, Blanas A, Akbari P, Roos A, et al. Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. Nat Commun. 2022;13(1):2842.PubMedPubMedCentralCrossRef van Beijnum JR, Huijbers EJM, van Loon K, Blanas A, Akbari P, Roos A, et al. Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy. Nat Commun. 2022;13(1):2842.PubMedPubMedCentralCrossRef
43.
go back to reference Bravaccini S, Bronte G, Petracci E, Puccetti M, D’Arcangelo M, Ravaioli S, et al. The expression of programmed death Ligand 1 and Vimentin in Resected Non-metastatic Non-small-cell Lung Cancer: interplay and Prognostic effects. Front Cell Dev Biol. 2021;9:772216.PubMedPubMedCentralCrossRef Bravaccini S, Bronte G, Petracci E, Puccetti M, D’Arcangelo M, Ravaioli S, et al. The expression of programmed death Ligand 1 and Vimentin in Resected Non-metastatic Non-small-cell Lung Cancer: interplay and Prognostic effects. Front Cell Dev Biol. 2021;9:772216.PubMedPubMedCentralCrossRef
44.
go back to reference Jiang J, Ying H. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment. J Exp Clin Cancer Res. 2022;41(1):244.PubMedPubMedCentralCrossRef Jiang J, Ying H. Revealing the crosstalk between nasopharyngeal carcinoma and immune cells in the tumor microenvironment. J Exp Clin Cancer Res. 2022;41(1):244.PubMedPubMedCentralCrossRef
45.
go back to reference Adkins DR, Haddad RI. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal carcinoma: a review. Cancer Treat Rev. 2022;109:102428.PubMedCrossRef Adkins DR, Haddad RI. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal carcinoma: a review. Cancer Treat Rev. 2022;109:102428.PubMedCrossRef
Metadata
Title
The E3 ligase NEURL3 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma by promoting vimentin degradation
Authors
Shi-Qing Zhou
Ping Feng
Ming-Liang Ye
Sheng-Yan Huang
Shi-Wei He
Xun-Hua Zhu
Jun Chen
Qun Zhang
Ying-Qing Li
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Metastasis
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-02945-9

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine